Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

The 18.00 level looks like put up or shut up to me :-)
Will watch patiently....

Should outperform the sector in the next 6 months and one of the picks in the FTSE 100 at this PE and given the likelihood of investor sentiment coming back into pharmas. IMHO it is unquestionably cheap and will be back trading at around 2000 before this month is out.Crestor RNS will confirm Japan licence mid January and then it can concentrate on global - a serious chance of this being a real blockbuster.

http://www.delawareonline.com/newsjournal/local/2005/01/08twostudiesoffer.html

Results due on thursday, someone bought 7 million this morning and a similiar amount on friday.
It is vulnerable to a takeover bid perhaps ?

Stubax
That is what I noticed on Friday and today.7m each time and paid over the offer price. Could this be stakebuilding excercise or somebody is very confident about the outcome of results on thursday. After all who would spend nearly 261m in 2 trading days?
Makes you think!

Looks like someone was confident about the outcome of the results. Have sold.

worth a read

http://yahoo.businessweek.com/technology/content/feb2005/tc2005027_1171_tc119.htm

A share that actually rises on ex. divi day...up 5p so far.

analysts have raised their forecasts recently and are looking at a price target of 23

Thanks Roro,

In that case I'll stick In there for a bit longer. Now up 10p.

Much obliged.

now up (34+18)52p. I think something is cooking here! Ratio of sells to buys is 2:1. We will know at the close if there are some big buy orders are pending to be executed.

You may well be right hjs but I've taken the profit just to be on the safe side.

FDA clears AstraZeneca's Crestor

AstraZeneca said that the US Food and Drug Administration has formally denied Public Citizen's Health Research Group's (HRG) petition to remove its Crestor cholesterol drug from the market.

The FDA's rejection of HRG's petition was based on an analysis of clinical trial safety data and post-marketing data, the company said.

The response letter from the FDA stated that all of the available evidence indicates that CRESTOR does not pose a risk of muscle toxicity greater than the other approved statins, and that with respect to renal toxicity, there is no convincing evidence that Crestor poses a serious risk of renal injury, AstraZeneca added.

Broker note from Matrix:
"AstraZeneca - we were looking for EPS Q$ US$1.52 AZN delivered US$1.42. Sales showed a decline in Q4 (because of generic competition to Toprol XL). Guidance for EPS full year is US$5.75 to 6.15 (we expected a range of US$6.,0 to 6.20...) there are likely to be downgrades given consensus is on US$6.00 like us but there are uncertainties surrounding further generic competition which is due to arrive this year. Company has guided to a mid single digit revenue decline and has stated that operating margins (pre R&D) are under pressure.
On the positive side - the company is now in a net cash position from net debt of US$7.1bn at the end of 2008

We still have the Stock at 2806 TP with a SELL recommendation. My feeling is a lot of people will be hiding in this stock for yield and with the recent competitor upgrades we could see some adjustment down of estimates from the street down to closer to our levels."

Trading statement due Thursday -
AstraZeneca will update the market on its third-quarter trading. Consensus figures suggest that analysts are expecting revenues of $8.2bn (5.1bn) compared to $7.9bn last time and pre-tax profits of $4bn compared to $2.26bn last time.

The City will be looking for signs of how sales of Astra's key brands such as cholesterol fighting Crestor are holding up.

Analysts will also be interested to hear about progress of the drug maker's new blood-thinning medicine, Brilinta.

JP Morgan Cazenove analysts were not predicting a particularly eventful set of results. They said that discussions are "likely to centre around how much of the AstraTech proceeds would be left for share buybacks in 2012 and Astra's future expectations for Crestor ahead of generic Lipitor in November 2011".

1st Quarter Results.

Pharmaceuticals group AstraZeneca will release its second-quarter statement on Thursday. Consensus estimates are for $6,800m of sales and earnings per share (EPS) of $1.40 in the three-month period. "Further cost cutting should support the near-term dividend, however we see a risk of EPS downgrades as AZN diverts money from share buybacks to pay for assets to refill the sales line," said analysts at Credit Suisse

PFIZER SENDS LETTER TO RT HON DAVID CAMERON MP

FIZER SENDS LETTER TO RT HON DAVID CAMERON MP
REGARDING COMMITMENTS IF PROPOSED COMBINATION WITH ASTRAZENECA IS COMPLETED


• Establishing the combined company's corporate and tax residence in England
• Substantial R&D innovation hub in Cambridge to be completed
• Key scientific leadership in the UK
• 20% of the combined company's total R&D workforce in the UK going forward
• Substantial commercial manufacturing facilities retained at Macclesfield
• European Business Headquarters and European Regulatory Headquarters to be located in the UK
• At least two AstraZeneca Board Members to join combined company's Board
• Board Meetings to be held in the UK as appropriate and meaningful participation in the UK commercial, economic and social community


Statement re Possible Offer

PFIZER CONFIRMS DELIVERY OF INCREASED PROPOSAL TO ASTRAZENECA

· Proposal represents a substantial premium of 32% for AstraZeneca shareholders[1]
· Proposal represents a 39% premium to the closing price of £35.86 on 3 January 2014, being the trading day immediately prior to the date of Pfizer's January proposal
· AstraZeneca shareholders would receive, for each AstraZeneca share, 1.845 shares in the combined company and 1,598 pence in cash, representing an indicative value of £50.00 ($84.47) per share[2]

Lots of broker notes around today.
Here's Deutsche Bank:
Pfizer has proposed an offer for AstraZeneca worth £50 per share which includes slightly higher equity and cash elements than the deal initially floated in private talks in January 2014 (the offer now stands at 1.845 Pfizer shares plus £15.98 in cash per AstraZeneca share vs 1.758 Pfizer shares plus £13.98 cash previously). While we expect this to be sufficient for AstraZeneca to enter into a dialogue, we strongly doubt this will gain the requisite AstraZeneca Board recommendation given that the new offer is pitched at just 7% above the January offer (which was dismissed in AstraZeneca’s press release earlier this week as “very significantly” undervaluing the company) … but we think offer needs to be sweetened with higher cash to be successful.
We expect Pfizer ultimately to have to sweeten its offer based on (1) discussions we have had with investors (many citing a price within the £52-55 range and some above this) and (2) our analysis of the EPS accretion for Pfizer which shows relatively limited sensitivity to increasing the cash component of its offer (given the low returns on cash). For example, were Pfizer to retain the equity component of its offer (ie, 1.845 Pfizer shares per AstraZeneca share) but to lift the cash element by £5/share, taking the offer to £55/share (with 38% cash), we calculate that year three accretion would be lowered by just 2% (from between 9-17% to 7-15%, based on hypothetical cost savings in the range of $2-4bn and assuming AstraZeneca’s tax rate applies to the whole group). By our calculations £55/share is roughly the point at which the NPV of the cost savings (taking the mid-point of the hypothetical $2-4bn range mentioned here) and tax benefits would equal the premium paid to the unaffected share price of circa £38/share before the press reports surfaced."

ASTRAZENECA BOARD REJECTS PFIZER PROPOSAL

The Board of AstraZeneca PLC ("AstraZeneca") has met and considered the letter from Pfizer Inc. ("Pfizer") (the "Proposal").

The financial and other terms described in the Proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer. The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged. Accordingly, the Board has rejected the Proposal.

Leif Johansson, Chairman of AstraZeneca, said: "AstraZeneca continues to invest significantly in research, development and manufacturing in the U.K., Sweden and the U.S. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders. Pfizer's proposal would dramatically dilute AstraZeneca shareholders' exposure to our unique pipeline and would create risks around its delivery. As such, the Board has no hesitation in rejecting the Proposal."

Shareholders are strongly advised to take no action. There can be no certainty that an offer will be made nor as to the terms on which any offer might be made.

A copy of this announcement will be available on AstraZeneca's website at www.astrazeneca.com.